Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis [0.03%]
接受pembrolizumab治疗的转移性尿路上皮癌的临床和血液学预后因素的系统评价和荟萃分析
Takafumi Yanagisawa,Keiichiro Mori,Satoshi Katayama et al.
Takafumi Yanagisawa et al.
Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic bioma...
Lital Oz-Alcalay,Sarah Elitzur,Nofar Amitai et al.
Lital Oz-Alcalay et al.
Background: COVID-19, the novel coronavirus, has caused a global pandemic affecting millions of people around the world. Risk factors for critical disease in adults are advanced age and underlying medical comorbidities, i...
Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study [0.03%]
术前肌少症是接受新辅助化放疗的下段直肠癌患者的不良预后因素：一项回顾性研究
Shinya Abe,Kazushige Kawai,Hiroaki Nozawa et al.
Shinya Abe et al.
Background: This study aimed to investigate the effect of sarcopenia on the prognosis of advanced lower rectal cancer patients receiving neoadjuvant chemoradiotherapy (CRT). Sarcopenia has been recognized as an adverse fa...
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis [0.03%]
新辅助化放疗与新辅助化疗在局部晚期食管癌治疗中的比较：基于人群的分析
Wei-Xiang Qi,Chunrong Chen,Shengguang Zhao et al.
Wei-Xiang Qi et al.
Aim: Currently, the optimal treatment strategy for locally advanced esophageal cancer (LAEC) remains controversial. We perform the present study to compare the outcomes of LAEC treated with neoadjuvant chemotherapy (neo-C...
Visceral-to-subcutaneous fat ratio is a possible prognostic factor for type 1 endometrial cancer [0.03%]
内脏与皮下脂肪比值可能是子宫内膜癌I型的预后因素
Michiko Wada,Ken Yamaguchi,Hajime Yamakage et al.
Michiko Wada et al.
Background: Associations have been observed between obesity defined by the body mass index (BMI) and the incidence of endometrial cancer. However, the impact of obesity on the prognosis of endometrial cancer is not yet cl...
Overweight and obesity as risk factors for biochemical recurrence of prostate cancer after radical prostatectomy [0.03%]
根治性前列腺切除术后体重超重和肥胖作为生化复发的风险因素的前列腺癌
Sung Jin Kim,Min Uk Park,Han Kyu Chae et al.
Sung Jin Kim et al.
Background: Previous studies have shown a relationship between the occurrence and recurrence of prostate cancer; however, this relationship remains controversial. We investigated the relationship between obesity and bioch...
The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy [0.03%]
术前肺免疫预后指数对根治性膀胱切除术的尿路上皮膀胱癌患者的预后价值
Koki Obayashi,Jun Miki,Wataru Fukuokaya et al.
Koki Obayashi et al.
Background: The lung immune prognostic index (LIPI) predicts the prognosis of patients with advanced non-small-cell lung cancer and is a prognostic biomarker for renal cell carcinoma and melanoma; however, no study has ev...
Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data [0.03%]
帕博西尼作为激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌日本患者早期治疗：临床试验和真实世界数据回顾
Norikazu Masuda,Nobuyoshi Kosaka,Hiroji Iwata et al.
Norikazu Masuda et al.
Breast cancer is the most common type of cancer among women worldwide and in Japan. The majority of breast cancers are hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2‒), and endocrine therapy is an e...
The expression and clinical significance of the tRNA aspartic acid methyltransferase 1 protein in gastric cancer [0.03%]
胃癌中tRNA天冬氨酸甲基转移酶1蛋白的表达及临床意义
Xia Sun,Xianting Huang,Xiangdong Lu et al.
Xia Sun et al.
Objectives: This study aimed to investigate the role of the tRNA aspartic acid methyltransferase 1 (TRDMT1) protein in the development and progression of gastric cancer (GC). ...
Establishment of nedaplatin safety dose formula based on renal function for combination chemotherapy with nedaplatin and 5-fluorouracil in patients with esophageal cancer [0.03%]
基于肾功能的奈达铂安全剂量公式建立在联合化疗中用于食管癌患者（奈达铂和5-氟尿嘧啶）
Masaya Takahashi,Katsuyuki Takahashi,Kazuya Muguruma et al.
Masaya Takahashi et al.
Background: It is known that the area under the plasma concentration curve of nedaplatin (AUCNDP) is associated with the relative reduction ratio of platelets and that the AUCNDP is based on nedaplatin dose normalized by ...